Your browser doesn't support javascript.
The Unique Properties of Placental Mesenchymal Stromal Cells: A Novel Source of Therapy for Congenital and Acquired Spinal Cord Injury.
Kulubya, Edwin S; Clark, Kaitlin; Hao, Dake; Lazar, Sabrina; Ghaffari-Rafi, Arash; Karnati, Tejas; Ebinu, Julius Okudu; Zwienenberg, Marike; Farmer, Diana L; Wang, Aijun.
  • Kulubya ES; Department of Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
  • Clark K; Department of Neurological Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
  • Hao D; Department of Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
  • Lazar S; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, CA 95817, USA.
  • Ghaffari-Rafi A; Department of Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
  • Karnati T; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, CA 95817, USA.
  • Ebinu JO; Department of Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
  • Zwienenberg M; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, CA 95817, USA.
  • Farmer DL; Department of Neurological Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
  • Wang A; Department of Neurological Surgery, Davis School of Medicine, University of California, Sacramento, CA 95817, USA.
Cells ; 10(11)2021 10 22.
Article in English | MEDLINE | ID: covidwho-1502368
ABSTRACT
Spinal cord injury (SCI) is a devasting condition with no reliable treatment. Spina bifida is the most common cause of congenital SCI. Cell-based therapies using mesenchymal stem/stromal cells (MSCS) have been largely utilized in SCI. Several clinical trials for acquired SCI use adult tissue-derived MSC sources, including bone-marrow, adipose, and umbilical cord tissues. The first stem/stromal cell clinical trial for spina bifida is currently underway (NCT04652908). The trial uses early gestational placental-derived mesenchymal stem/stromal cells (PMSCs) during the fetal repair of myelomeningocele. PMSCs have been shown to exhibit unique neuroprotective, angiogenic, and antioxidant properties, all which are promising applications for SCI. This review will summarize the unique properties and current applications of PMSCs and discuss their therapeutic role for acquired SCI.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Placenta / Spinal Cord Injuries / Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells Type of study: Prognostic study / Randomized controlled trials Limits: Female / Humans / Pregnancy Language: English Year: 2021 Document Type: Article Affiliation country: Cells10112837

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Placenta / Spinal Cord Injuries / Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells Type of study: Prognostic study / Randomized controlled trials Limits: Female / Humans / Pregnancy Language: English Year: 2021 Document Type: Article Affiliation country: Cells10112837